SI2854768T1 - Farmacevtski sestavki pemetrekseda - Google Patents

Farmacevtski sestavki pemetrekseda

Info

Publication number
SI2854768T1
SI2854768T1 SI201330666T SI201330666T SI2854768T1 SI 2854768 T1 SI2854768 T1 SI 2854768T1 SI 201330666 T SI201330666 T SI 201330666T SI 201330666 T SI201330666 T SI 201330666T SI 2854768 T1 SI2854768 T1 SI 2854768T1
Authority
SI
Slovenia
Prior art keywords
pemetrexed
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
SI201330666T
Other languages
English (en)
Inventor
Dhiraj Khattar
Rajesh Khanna
Mukti Yadav
Krishanu Burman
Original Assignee
Fresenius Kabi Oncology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2854768(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Oncology Limited filed Critical Fresenius Kabi Oncology Limited
Publication of SI2854768T1 publication Critical patent/SI2854768T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI201330666T 2012-05-30 2013-05-30 Farmacevtski sestavki pemetrekseda SI2854768T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1648DE2012 2012-05-30
PCT/IB2013/054456 WO2013179248A1 (en) 2012-05-30 2013-05-30 Pharmaceutical compositions of pemetrexed
EP13730070.3A EP2854768B1 (en) 2012-05-30 2013-05-30 Pharmaceutical compositions of pemetrexed

Publications (1)

Publication Number Publication Date
SI2854768T1 true SI2854768T1 (sl) 2017-08-31

Family

ID=48656253

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330666T SI2854768T1 (sl) 2012-05-30 2013-05-30 Farmacevtski sestavki pemetrekseda

Country Status (8)

Country Link
US (2) US9421207B2 (sl)
EP (2) EP2854768B1 (sl)
DK (1) DK2854768T3 (sl)
ES (1) ES2624442T3 (sl)
LT (1) LT2854768T (sl)
PT (1) PT2854768T (sl)
SI (1) SI2854768T1 (sl)
WO (1) WO2013179248A1 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3308770A1 (en) * 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
US20160143911A1 (en) * 2013-06-14 2016-05-26 Synthon B.V. Stable and water soluble pharmaceutical compositions comprising pemetrexed
WO2015008221A1 (en) * 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
DK3040074T3 (en) 2013-10-03 2018-10-08 Fujifilm Corp INJECTION PREPARATION AND METHOD OF PREPARING IT
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
PL3124026T3 (pl) * 2014-03-28 2019-03-29 Fujifilm Corporation Preparat iniekcyjny i sposób jego wytwarzania
GB201418555D0 (en) * 2014-10-16 2014-12-03 Teva Gmbh Pemetrexed formulations
HUE048357T2 (hu) 2014-10-16 2020-08-28 Synthon Bv Pemetrexedet tartalmazó folyékony gyógyszerészeti kompozíció
ES2928018T3 (es) 2015-02-13 2022-11-15 Sun Pharmaceutical Ind Ltd Forma de dosificación para infusión intravenosa
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
GB201511246D0 (en) * 2015-06-25 2015-08-12 Actavis Group Ptc Ehf Pharmaceutical formulation
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP2019505561A (ja) * 2016-02-19 2019-02-28 イーグル ファーマシューティカルズ， インコーポレイテッド ペメトレキセド製剤
US20170239250A1 (en) * 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
US20200246263A1 (en) * 2017-08-29 2020-08-06 Fresenius Kabi Oncology Limited Stable liquid compositions of pemetrexed
US20190105262A1 (en) 2017-10-10 2019-04-11 Sun Pharmaceutical Industries Ltd. Intravenous infusion dosage form for pemetrexed
CN108158989B (zh) * 2018-03-01 2020-08-28 河北爱尔海泰制药有限公司 一种盐酸氨溴索注射液组合物
US10966982B2 (en) 2018-11-20 2021-04-06 Cipla Limited Stable pharmaceutical formulations of pemetrexed
US20220211709A1 (en) * 2019-05-01 2022-07-07 Intas Pharmaceuticals Ltd. Stable, ready to use aqueous pharmaceutical composition of pemetrexed
JPWO2021192472A1 (sl) * 2020-03-24 2021-09-30
JP7282065B2 (ja) * 2020-10-05 2023-05-26 イーグル ファーマシューティカルズ， インコーポレイテッド ペメトレキセド製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005798A1 (en) 1987-12-18 1989-06-29 Ciba-Geigy Ag TROMETHAMINE SALT OF 1-METHYL-beta-OXO-alpha-(PHENYLCARBAMOYL)-2-PYRROLEPROPIONITRILE
IL96531A (en) 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
DK1313508T5 (da) 2000-06-30 2017-03-20 Lilly Co Eli Kombination indeholdende et antifolat og methylmalonsyresænkende middel
CN100364993C (zh) 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
EP1818049A3 (en) 2006-02-10 2008-11-19 LifeCycle Pharma A/S Stabilized Atorvastatin
CN101081301A (zh) 2006-05-29 2007-12-05 海南天源康泽医药科技有限公司 含有培美曲塞的药物组合物
DE602007011384D1 (de) 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
IT1401207B1 (it) 2010-06-30 2013-07-12 Magic Production Group S A Dispositivo e procedimento per la chiusura di contenitori
EP2598148A4 (en) 2010-07-28 2014-05-28 Eagle Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS CONTAINING PEMETREXED HAVING EXTENDED STORAGE STABILITY
EP3308770A1 (en) 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation

Also Published As

Publication number Publication date
LT2854768T (lt) 2017-06-12
EP3210629A1 (en) 2017-08-30
US20150111905A1 (en) 2015-04-23
US20160310495A1 (en) 2016-10-27
US9421207B2 (en) 2016-08-23
EP2854768A1 (en) 2015-04-08
PT2854768T (pt) 2017-05-19
DK2854768T3 (en) 2017-06-12
WO2013179248A1 (en) 2013-12-05
US9968608B2 (en) 2018-05-15
ES2624442T3 (es) 2017-07-14
EP2854768B1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
SI2854768T1 (sl) Farmacevtski sestavki pemetrekseda
HK1209638A1 (en) Pharmaceutical compositions
GB201113662D0 (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
HK1199824A1 (en) Pharmaceutical compositions
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
IL237139A0 (en) Pharmaceutical compositions of memantine
IL266415A (en) Innovative pharmaceutical composition
PL2887924T3 (pl) Kompozycje farmaceutyczne etorykoksybu
GB201118181D0 (en) Pharmaceutical compositions
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
EP2884964A4 (en) PHARMACEUTICAL COMPOSITION OF PROPOFOL
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
EP2714715A4 (en) PHARMACEUTICAL COMPOSITIONS
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition